Literatur
-
1
Christians U, Jacobsen W, Floren L C.
Metabolism
and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors in transplant patients: are the statins mechanistically
similar?.
Pharmacol Ther.
1998;
80
1-34
-
2
Cosio F G, Pesavento T E, Pelletier R P. et al .
Patient survival
after renal transplantation III: the effects of statins.
Am
J Kidney Dis.
2002;
40
638-643
-
3
Fellstrom B.
Impact
and management of hyperlipidemia posttransplantation.
Transplantation.
2000;
70
SS51-57
(Suppl 11)
-
4
Holdaas H, Fellstrom B, Holme I. et al .
Effects of fluvastatin on cardiac events
in renal transplant patients: ALERT (Assessment of Lescol in Renal
Transplantation) study design and baseline data.
J Cardiovasc Risk.
2001;
8
63-71
-
5
Holdaas H, Jardine A G, Wheeler D C. et al .
Effect of fluvastatin on
acute renal allograft rejection: a randomized multicenter trial.
Kidney
Int.
2001;
60
1990-1997
-
6
Holdaas H, Julian D.
The use of statins after
solid organ transplantation.
Nephrol Dial Transplant.
2002;
17
1537
-
7
Jardine A, Holdaas H.
Fluvastatin in combination
with cyclosporin in renal transplant recipients: a review of clinical
and safety experience.
J Clin Pharm Ther.
1999;
24
397-408
-
8
Kasiske B L.
Role
of circulating lipid abnormalities in chronic renal allograft rejection.
Kidney
Int Suppl.
1999;
71
28-30
-
9
Lindholm A, Albrechtsen D, Frodin L. et al .
Ischemic heart disease - major
cause of death and graft loss after renal transplantation in Scandinavia.
Transplantation.
1995;
60
451-457
-
10
Mach F.
Immunosuppressive
effects of statins.
Atheroscler Suppl.
2002;
3
17-20
-
11
Mehra M R, Uber P A, Vivekananthan K. et al .
Comparative beneficial effects
of simvastatin and pravastatin on cardiac allograft rejection and
survival.
J Am Coll Cardiol.
2002;
40
1609-1614
-
12
Omar M A, Wilson J P.
FDA adverse
event reports on statin-associated rhabdomyolysis.
Ann
Pharmacother.
2002;
36
288-295
-
13
Stirling C M, Isles C G.
Rhabdomyolysis
due to simvastatin in a transplant patient: Are some statins safer
than others?.
Nephrol Dial Transplant.
2001;
16
873-874
-
14
Wanner C, Quaschning T, Weingarnter K.
Impact
of dyslipidaemia in renal transplant recipients.
Curr
Opin Urol.
2000;
10
77-80
-
15
Wood D, De Backer G, Faergeman O. et al .
Prevention of coronary heart disease in
clinical practice. Summary of recommendations of the Second Joint
Task Force of European and other Societies on Coronary Prevention.
Blood
Press.
1998;
7
262-269
Dr. Lutz Fritsche
Med. Klinik m. S. Nephrologie, Charité Campus
Mitte
Schumannstraße 20/21
10098
Berlin
Telefon: 030/450514009/-002
Fax: 030/450514902
eMail: Lutz.Fritsche@charite.de
